Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Queen Mary University of London · UCSF Helen Diller Family Comprehensive Cancer Center · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,189
total citations
- FWCI
- 66.99
- Percentile
- 100%
- References
- 25
Citations per year
Authors
15- PSPeter SchmidCorresponding
Queen Mary University of London
- HSHope S. Rugo
UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
- SASylvia Adams
NYU Langone Health
- ASAndreas Schneeweiß
German Cancer Research Center, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg University
- CHCarlos H. Barrios
Pontifícia Universidade Católica do Rio Grande do Sul
Topics & keywords
Topics
Keywords
- Atezolizumab
- Medicine
- Triple-negative breast cancer
- Oncology
- Internal medicine
- Placebo
- Paclitaxel
- Metastatic breast cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.